

<i>Product Licence Number</i>	<i>Company Name</i>	<i>Product Name</i>	<i>Active Ingredients</i>	<i>Indications</i>	<i>Date of Authorisation</i>
6679/0057	Polyfarma Limited	Zyloric 300 mg Tablets	Allopurinol 300.0 mg	<p>Zyloric is used to reduce urate concentrations in body fluids and/or urine to prevent or reverse the deposition of urate/uric acid. Zyloric is indicated for the main clinical manifestations of urate/uric deposition. These are gouty arthritis, skin tophi and/or renal involvement through crystal deposition on stout formation. Such clinic-al manifestations occur in: idiopathic gout, uric acid lithiasis, acute uric acid nephropathy, neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy; certain enzyme disorders which lead to over production or urate and involve: hypoxanthine guanine phosph-horibosyltran sferase (including lesch-nyhan syndrome), glucose-6-phosph-atase (including glycogen storage disease), phos phoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase, adenine phosph-hori bosyltransferase, glutathione reductase, glutamate dehydrogenase. Zyloric is indicated for the management of 2,8-dihydroxyadenine (2,8-DHA) renal stones related to deficient activity of adenine phosphoribosyltransferase. Zyloric is indicated for the management of recurrent mixed calcium oxal-ate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.</p> <p>POM</p>	26th June 1993
8142/0003	Norton (Waterford) Limited	Beclomethasone Dipropionate Inhaler 50 ug or Beclazone 50 Inhaler	Beclomethasone Dipropionate (as propellant 11 Solvate) HSE 50 ug	<p>(i) Treatment of patients whose asthma is becoming worse, and the relief provided by bronchodilators is less effective.</p> <p>(ii) Treatment of patients with severe asthma who are dependent on systemic corticosteroids or adrenocorticotrophic hormone (ACTH) or its synthetic equivalent.</p> <p>(iii) Treatment of patients who are inadequately controlled by sodium cromoglycate in addition to bronchodilators.</p> <p>(iv) Particularly important for managing servere asthma in children because good control can be achieved without retardation of growth.</p> <p>POM</p>	28th May 1993